Hisky Medical

What Hisky Medical does

Hisky Medical (无锡海斯凯尔医学技术有限公司 / Wuxi Haiscale Medical Technology Co., Ltd.) is a Wuxi-headquartered, Tsinghua University-originated medical device company founded in 2010 that develops and commercializes non-invasive diagnostic systems for liver disease and adjacent clinical specialties. The company's core technology stack is built on Vibration-Controlled Transient Elastography (TE) combined with Ultrasound Attenuation Parameter (UAP), embodied in the iLivTouch platform (rebranded from FibroTouch in 2022) which provides quantitative Liver Stiffness Measurement (LSM) and steatosis assessment within minutes without requiring liver biopsy. The product portfolio has expanded to include CelTouch, a confocal laser endomicroscopy platform enabling real-time in vivo cellular imaging at 1000x magnification for optical biopsy across gastroenterology, respiratory, and urology applications, and EQTouch, a high-end research ultrasound system with 128-1024 parallel channels. Supporting technologies include LivQ-box (LIID parameter for MASH inflammation quantification) and MigTE (multi-modal fusion probe technology with 1000x the sampling range of biopsy).

The company generates revenue through direct enterprise sales of capital medical equipment to hospitals and healthcare institutions, supplemented by recurring revenue from consumable probes (requiring calibration and replacement every 30,000 cycles), accessories, and professional services including installation, calibration, and technical training. Distribution combines a direct regional sales force covering Europe, Africa, Middle East, CIS, APAC, North America, and Latin America with a network of distributor partners across 60+ countries; the company hosts annual partner meetings for training and coordination. The customer base is concentrated in tertiary and secondary hospitals with gastroenterology, hepatology, endocrinology, and physical examination departments, with named deployments across China, Spain, Vietnam, Egypt, and other markets. Five thousand-plus units have been installed globally, supported by certifications across all major regulatory jurisdictions (FDA, CE, PMDA, TGA, KFDA, RZN, NMPA). Cumulative funding of approximately $44 million has been raised across three rounds from 2016-2025, with strategic partnerships signed with GE HealthCare (2025), Omron (2026), and Guangzhou National Laboratory (2026) to expand into adjacent diagnostic and chronic disease management verticals.

Name

Hisky Medical

Legal name

Wuxi Haiscale Medical Technology Co., Ltd. (无锡海斯凯尔医学技术有限公司)

Website

https://hiskymedical.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

Hisky Medical is a Chinese medical device company that develops and sells non-invasive liver diagnostic systems based on vibration-controlled transient elastography, plus confocal laser endomicroscopy platforms, primarily serving tertiary hospitals, hepatology departments, and health screening centers across 60+ countries.

Ownership category

akta.pro rank

Product category

Medical Diagnostic Equipment

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics) (HLAHAAAE)

Keywords

• Non-invasive liver diagnostics
• Transient elastography systems
• Confocal laser endomicroscopy
• Liver fibrosis assessment
• Medical imaging equipment

Headquarters

HQ city

Haidian

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Medical Device Hardware Sales: Sale of medical diagnostic equipment including iLivTouch liver detection systems, CelTouch confocal endomicroscopy devices, and EQTouch ultrasound platforms. Equipment sales to hospitals, medical institutions, and healthcare providers globally.
2. Probe and Accessory Sales: Recurring revenue from consumable probes requiring periodic calibration and correction every 30,000 cycles, as well as other accessories and replacement parts.
3. Professional Services and Support: Technical training, installation, calibration, and after-sales support services for medical equipment, including hands-on medical and technical training for global partners.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Core offering

Hisky Medical develops, manufactures, and sells non-invasive medical diagnostic devices for liver disease assessment and cellular imaging. Core products include the iLivTouch Vibration-Controlled Transient Elastography (TE) system for measuring liver fibrosis (LSM) and steatosis (UAP), the CelTouch confocal laser endomicroscopy platform for real-time in vivo cellular imaging during endoscopic procedures, and the EQTouch high-end research ultrasound system. Recurring revenue is generated through proprietary probe sales and professional services including installation, training, and calibration.

Product overview

Hisky Medical offers a multi-product portfolio centered around non-invasive medical diagnostics, particularly for liver disease management. The core offerings include: (1) iLivTouch Non-invasive Liver Disease Management System - a Vibration-Controlled Transient Elastography (TE)-based platform providing Liver Stiffness Measurement (LSM) and Ultrasound Attenuation Parameter (UAP) for assessing liver fibrosis and steatosis, available in Max, Plus, Pro, and Mini series configurations; (2) CelTouch Confocal Laser Endomicroscopy Platform - enabling real-time in vivo cellular imaging for precision diagnosis across gastroenterology, respiratory, and urology applications; and (3) EQTouch High-end Ultrasound Platform - a research-oriented system with advanced imaging capabilities. Supporting technologies include LivQ-box for liver inflammation quantification and MigTE multi-modal fusion probes. The portfolio covers non-invasive screening, diagnosis, and post-diagnosis management in liver, digestion, endocrine, physical examination, respiratory, breast, urology, and surgery fields.

Differentiator

Problem solved

Functional benefit

Brands

• iLivTouch: Non-invasive Liver Disease Management System - non-invasive liver diagnostic system powered by Transient Elastography (TE) technology
• CelTouch
• EQTouch
• LivQ-box
• MigTE

Products and services

• iLivTouch Non-invasive Liver Disease Management System A comprehensive non-invasive liver diagnostic system based on Vibration-Controlled Transient Elastography (TE) technology. Provides rapid, quantitative assessment of liver fibrosis (Liver Stiffness Measurement - LSM) and steatosis (Ultrasound Attenuation Parameter - UAP), enabling earlier detection and better disease management. Available in Max, Plus, Pro, and Mini series configurations. For hospitals, hepatology departments, and physical examination centers.
• CelTouch Confocal Laser Endomicroscopy (CLE) Platform An innovative confocal laser endomicroscopy platform offering real-time, in vivo cellular imaging at 1000-fold magnification to support precision diagnosis, optical biopsy, and targeted treatment decisions. Can be used in conjunction with various types of endoscopes to achieve non-invasive, in vivo, and real-time optical pathological imaging. Applicable in gastroenterology, respiratory, urology and other departments.
• EQTouch High-end Ultrasound Research System A high-end ultrasound platform for scientific research applications featuring 128-1024 parallel physical channels, 50,000 frames per second high-speed imaging, and lossless storage of full-channel RF data. Supports multimodal functions for scientific research across multiple fields including RF data, micro-blood flow data acquisition, and viscoelasticity measurement.

Quantifiable outcome

• FibroTouch UAP diagnostic accuracy for NAFLD liver steatosis: AUROC 0.95 (≥5%), 0.86 (≥10%), 0.90 (≥20%) versus MRI-PDFF reference standard
• +4 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

Partnerships

Four partnerships are on record, tiered core and flagship.

• OmroncoreStrategic or Co-development Partner · 9 April 2026Strategic cooperation agreement signed at CMEF 2026 for chronic disease management sector collaboration. Hisky provides core non-invasive liver detection technologies for liver fibrosis and hepatic steatosis assessment. Partnership leverages Omron's experience in chronic disease management programs including cardiovascular disease prevention, hypertension/hyperglycemia/hyperlipidemia control, and standardized Metabolic Management Centers (MMC) to develop integrated chronic disease management solutions.
• Guangzhou National LaboratorycoreStrategic or Co-development Partner · 15 January 2026Collaboration on national-level project titled 'Diagnostic Value of Confocal Endoscopy CelTouch for Peripheral Pulmonary Lesions' under Guangzhou National Laboratory's major research initiative. Multi-center launch meetings held at leading hospitals including Emergency General Hospital, Beijing Hospital, First Affiliated Hospital of Zhengzhou University, Hunan Provincial People's Hospital, Shanghai Pulmonary Hospital, and Guangdong Provincial People's Hospital to evaluate CelTouch's clinical value in distinguishing benign and malignant lesions.
• GE HealthCare ChinaflagshipStrategic or Co-development Partner · 5 November 2025Strategic MOU signed at the 8th China International Import Expo (CIIE) to co-develop integrated, data-driven diagnostic and treatment solutions for chronic liver disease. Collaboration combines Hisky's iLivTouch non-invasive liver assessment system with GE HealthCare's advanced ultrasound and intelligent imaging platforms for integrated liver disease diagnosis, treatment, and long-term follow-up solutions targeting China's estimated 400 million chronic liver disease patients.
• Tsinghua UniversitycoreStrategic or Co-development PartnerHisky Medical originated from Tsinghua University's Department of Biomedical Engineering. Professor Bai Jing from Tsinghua University initiated elastography technology research in 1993. Ongoing collaboration with Tsinghua includes technology development, talent recruitment, and academic research partnerships contributing to key national R&D initiatives.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Echosens: Echosens (FibroScan) is the global market leader in vibration-controlled transient elastography for non-invasive liver fibrosis and steatosis assessment, the exact product category where Hisky's iLivTouch competes directly. Both companies target hepatology departments, gastroenterology clinics, and metabolic disease centers with comparable TE-based quantitative liver diagnostics.
• Mindray: Mindray is a leading Chinese medical device manufacturer with a broad diagnostic imaging and patient monitoring portfolio that overlaps Hisky's EQTouch research ultrasound and ultrasound-based diagnostic systems. Both companies are large-scale Chinese device manufacturers serving global hospital channels.

Broad incumbents

• Siemens Healthineers: Siemens Healthineers offers comprehensive ultrasound, MR elastography (via Resoundant partnership), and liver imaging solutions as part of a broad diagnostic imaging portfolio. While not specializing in standalone elastography, Siemens competes for the same hospital capital budgets that Hisky targets and represents a major incumbent alternative in liver diagnostics.
• GE HealthCare: GE HealthCare is a global incumbent in ultrasound, imaging, and integrated diagnostic solutions. While Hisky is also a strategic MOU partner, GE remains a broader incumbent whose ultrasound platforms compete with Hisky's iLivTouch in liver assessment workflows across large hospital systems worldwide.
• Philips Healthcare: Philips offers ultrasound systems (EPIQ, Affiniti) and integrated liver imaging workflows that overlap with Hisky's elastography and ultrasound product lines. As a diversified imaging incumbent, Philips competes for the same hospital procurement budgets and hepatology workflow integration deals.
• Canon Medical Systems: Canon Medical Systems produces diagnostic ultrasound and imaging systems used in hepatology and gastroenterology workflows. As a major incumbent in the imaging modality space, Canon competes with Hisky for liver assessment and screening deployments.
• Olympus Medical: Olympus is the global leader in endoscopy systems and a key player in confocal laser endomicroscopy through its Cellvizio platform, which is the closest direct competitor to Hisky's CelTouch. Olympus also competes in gastroenterology procedure workflows where Hisky's products are deployed.
• Fujifilm Healthcare: Fujifilm Healthcare provides endoscopy, ultrasound, and diagnostic imaging systems used in hepatology and gastroenterology. As a broad incumbent in endoscopy and imaging, Fujifilm competes with Hisky's CelTouch endomicroscopy platform for procedure-room diagnostic deployments.

Emerging players

• Resoundant: Resoundant develops MR elastography (MRE) technology for non-invasive liver fibrosis assessment, offering an alternative modality to Hisky's ultrasound-based transient elastography. Resoundant partners with MRI manufacturers (Siemens, GE) to integrate liver stiffness measurement into MRI workflows, competing for the same clinical decision-making context.
• EchoNous: EchoNous develops point-of-care ultrasound and AI-enabled diagnostic tools that intersect with Hisky's portable ultrasound and elastography products. While focused on different clinical settings, EchoNous represents an emerging player pushing ultrasound diagnostics toward primary care and bedside use cases adjacent to Hisky's liver screening ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@hiskymedical
• LinkedInlinkedin.com/company/15251844
• Xx.com/FibroTouch
• Facebookfacebook.com/Hisky-Medical-1247584748639118

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds4 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hisky Medical